Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Europe’s Big Pharma Players Begin Tricky 2022 In Style

May 19 2022

• By Kevin Grogan

Tightrope — • Source: Shutterstock

Related Content

Sanofi Dives Back Into ADCs With Seagen Pact

Mar 17 2022

Sanofi Bets Big On IgM ‘Super Antibodies’ In Potential $6bn Cancer and Immunology Deal

Mar 29 2022

D-Day Approaches For Bayer’s Asundexian Phase III Plans

May 10 2022

Dupixent Drives Sanofi Growth Again Amid Pipeline Renewal

Apr 28 2022

GSK Gets A Lucky Q1 Boost, But All Eyes Are On RSV Vaccine Readout

Apr 27 2022

Novartis’s Kesimpta Already A Big Earner But Leqvio Is Slow Burner

Apr 26 2022

Roche's SERD Setback Means Menarini Retains An Edge

Apr 25 2022

Novo’s Wegovy Excels But Lilly Rival Hot On Heels

Apr 29 2022

AstraZeneca’s Farxiga Flies Across $1bn Barrier

Apr 29 2022

Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise

May 13 2022

Blow To Roche Growth Prospects As TIGIT Lung Cancer Trial Fails

May 11 2022

Slowing COVID-19 Sales Will Drag On Roche In 2022

Feb 03 2022

Related Companies

AstraZeneca PLC

GSK plc

Roche Holding AG

Novartis AG

Sanofi

IGM Biosciences, Inc.

Seagen Inc.

Bayer AG

Johnson & Johnson

Pfizer Inc.

Bristol Myers Squibb Company

Novo Nordisk A/S

Eli Lilly and Company

Additional Topics

Europe Growth Market Intelligence BioPharmaceutical

More from Global Vision

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window